Ticker

Analyst Price Targets — ABSI

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
June 25, 2026 10:46 amMorgan Stanley$10.00$10.08TheFly Absci price target raised to $10 from $4.10 at Morgan Stanley
June 25, 2026 10:01 amH.C. Wainwright$16.00$10.08TheFly Absci price target raised to $16 from $8 at H.C. Wainwright
June 15, 2026 10:40 amGuggenheim$15.00$6.80TheFly Absci price target raised to $15 from $10 at Guggenheim
June 4, 2026 10:30 amLeerink Partners$12.00$5.94TheFly Absci initiated with an Outperform at Leerink
May 28, 2026 10:39 amBTIG$9.00$5.16TheFly Absci initiated with a Buy at BTIG
May 14, 2026 12:01 pmMorgan Stanley$4.10$5.62TheFly Absci price target lowered to $4.10 from $4.20 at Morgan Stanley
January 8, 2026 11:14 amMorgan Stanley$4.32$4.02TheFly Absci downgraded to Equal Weight from Overweight at Morgan Stanley
December 17, 2025 5:38 pmH.C. Wainwright$8.00$3.44TheFly Absci price target raised to $8 from $7 at H.C. Wainwright
March 21, 2024 1:40 pmDaniel AriasStifel Nicolaus$6.00$5.28StreetInsider Absci Corp. (ABSI) PT Raised to $6 at Stifel

Latest News for ABSI

Absci Q2 Earnings Call Highlights

Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis, while reporting a larger cash balance following a June equity offering and strategic investment from Eli Lilly.

MarketBeat • Aug 11, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ABSI.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top